GLP 1(1-37)(人类结构式
|
常用名 | GLP 1(1-37)(人类 | 英文名 | GLP-1 (1-37) (human, bovine, guinea pig, mouse, rat) trifluoroacetate salt |
---|---|---|---|---|
CAS号 | 87805-34-3 | 分子量 | 4169.48 | |
密度 | N/A | 沸点 | N/A | |
分子式 | C186H275N51O59 | 熔点 | N/A | |
MSDS | 美版 | 闪点 | N/A |
GLP 1(1-37)(人类用途Glucagon-like peptide 1 (1-37), human是有效的 GLP-1 受体激动剂。 |
中文名 | 血糖素样肽-1 |
---|---|
英文名 | GLP-1 (1-37) amide |
英文别名 | 更多 |
描述 | Glucagon-like peptide 1 (1-37), human是有效的 GLP-1 受体激动剂。 |
---|---|
相关类别 | |
靶点 |
GLP-1 receptor[1] |
体外研究 | 胰高血糖素样肽-1(GLP-1)通过胰高血糖素原的翻译后加工产生,并且充当各种稳态事件的调节剂。 GLP-1(1-37)比GLP-1(7-37)更稳定,在暴露于小鼠血清4小时后剩余94.7%的肽初始量。通过测量瞬时转染的人胚肾(HEK293)细胞中荧光素酶报告基因表达的表达,证实GLP-1(1-37)是GLP-1受体(GLP-1R)的高效激动剂[1]。 。 |
体内研究 | GLP-1(1-37)以剂量依赖性降低血糖波动。与对照组相比,GLP-1(1-37)或GLP-1(7-37)的给药在15分钟和30分钟时显着降低血糖水平[1]。 |
细胞实验 | 将HEK293细胞(5×104)接种在96孔板中,并用GLP-1R质粒和CRE-荧光素酶报道质粒瞬时共转染。转染48小时后,加入不同浓度的GLP-1(1-37)或GLP-1(7-37),将细胞培养5小时。使用荧光素酶测定法收获细胞用于荧光素酶测定[1]。 |
动物实验 | 小鼠[1]在施用(ip)GLP-1和葡萄糖之前,将正常KM小鼠禁食16小时。将含有或不含毒蜥外泌肽(9-39)(250nmol / kg)的GLP-1(1-37)(25nmol / kg)与葡萄糖(4g / kg)组合给予。具有或不具有毒蜥外泌肽(9-39)(250nmol / kg)的GLP-1(7-37)(25nmol / kg)也与葡萄糖(4g / kg)组合施用。对照组用盐水(NaCl,9g / l)和葡萄糖(4g / kg)处理。在葡萄糖和蛋白质给药后0,15,30和60分钟进行IPGTT,并如上所述测量血糖水平[1]。 |
参考文献 |
分子式 | C186H275N51O59 |
---|---|
分子量 | 4169.48 |
储存条件 | −20°C |
个人防护装备 | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
---|---|
危险品运输编码 | NONH for all modes of transport |
WGK德国 | 3 |
GLP-1-related proteins attenuate the effects of mitochondrial membrane damage in pancreatic β cells.
Biochem. Biophys. Res. Commun. 447(1) , 133-8, (2014) Glucagon-like peptide (GLP)-1 analog based therapies are used not only for their insulinotropic effects, but also for their pleiotropic effects that improve pancreatic β cell function. Liraglutide is ... |
|
Glucagon-like peptide-1 and blood pressure in young and healthy adults from the general population.
Hypertension 65(2) , 306-12, (2015) Hypertension and diabetes mellitus are highly correlated, but the underlying mechanisms are only partly understood. Therefore, the aim of our study was to investigate the relationships between plasma ... |
|
The low level of glucagon-like peptide-1 (glp-1) is a risk factor of type 2 diabetes mellitus.
BMC Res. Notes 7 , 849, (2014) Glucagon like peptide-1 (GLP-1), an incretin hormone, regulates glucose metabolism by inducing insulin secretion and suppressing glucagon secretion. The aim of the study is to assess the levels of fas... |
Glucagon-like peptide 1 (1-37) |
Glucagon-like peptide 1 (1-37) (human, rat) |
Glucagon-like peptide 1 (1-37), human |